Oncolytics Biotech
ONCY
21 hedge funds and large institutions have $284K invested in Oncolytics Biotech in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.2% less ownership
Funds ownership: 1.13% → 0.93% (-0.2%)
60% less capital invested
Capital invested by funds: $707K → $284K (-$423K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$121K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.5K |
| 3 |
HNB
Huntington National Bank
Columbus,
Ohio
|
+$2.85K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.28K |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$569 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$180K |
| 2 |
Renaissance Technologies
New York
|
-$61K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$39.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$14.2K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$11.8K |
ONCY Hedge Fund Activity: Q4 2018 in Review
21 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2018, worth a combined $284K — down 60% from $707K a quarter earlier.
Fund positioning in ONCY was balanced in Q4 2018: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was Scotia Capital, opening a new position worth an estimated $121K. The largest seller was Millennium Management, exiting entirely with an estimated $180K sold.
- 21 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $284K of Oncolytics Biotech stock for Q4 2018, down 60% quarter-over-quarter.
- 5 funds opened new Oncolytics Biotech positions in Q4 2018 and 5 closed out, a net change of 0 holders.
- The largest Oncolytics Biotech buyer in Q4 2018 was Scotia Capital, an estimated $121K added.
- The largest Oncolytics Biotech seller in Q4 2018 was Millennium Management, an estimated $180K sold.
Based on aggregated 13F filings for Q4 2018.